Biochemical markers of joint tissue damage increase shortly after a joint bleed; An explorative human and canine invivo study

Osteoarthritis and Cartilage

Volumn 23, Issue 1, 2015, Pages 63-69

  van Vulpen, L F D ^a,b   van Meegeren, M E R ^a,b   Roosendaal, G ^a   Jansen, N W D ^a,b   van Laar, J M ^b   Schutgens, R E G ^a   Mastbergen, S C ^b   Lafeber, F P J G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Arthropathy; Biochemical markers; Cartilage; Haemarthrosis

Indexed keywords

BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE CLEAVAGE PRODUCT; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHONDROITIN SULFATE 846; COLLAGEN TYPE 3; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VIVO STUDY; JOINT INJURY; NONHUMAN; URINALYSIS; ADOLESCENT; ADULT; AGED; ANIMAL; BLOOD; COMPLICATION; FEMALE; JOINT DISEASES; MALE; MIDDLE AGED; TIME; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; DOGS; FEMALE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; JOINT DISEASES; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84918788600     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.09.008     Document Type: Article

References (37)

1. Lafeber F.P., Miossec P., Valentino L.A. Physiopathology of haemophilic arthropathy. Haemophilia 2008, 14(Suppl 4):3-9.
2. Guermazi A., Hayashi D., Roemer F.W., Felson D.T. Osteoarthritis: a review of strengths and weaknesses of different imaging options. Rheum Dis Clin North Am 2013, 39:567-591.
3. Colebatch A.N., Edwards C.J., Ostergaard M., van der Heijde D., Balint P.V., D'Agostino M.A., et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013, 72:804-814.
4. Doria A.S. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010, 16(Suppl 5):107-114.
5. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
6. van Spil W.E., DeGroot J., Lems W.F., Oostveen J.C., Lafeber F.P. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010, 18:605-612.
7. Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377:2115-2126.
8. Viatte S., Plant D., Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013, 9:141-153.
9. Lafeber F.P., van Spil W.E. Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time. Osteoarthritis Cartilage 2013, 21:1452-1464.
10. Fischer K., Collins P., Bjorkman S., Blanchette V., Oh M., Fritsch S., et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia 2011, 17:433-438.
11. Roosendaal G., van Rinsum A.C., Vianen M.E., van den Berg H.M., Lafeber F.P., Bijlsma J.W. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999, 34:144-153.
12. Hakobyan N., Enockson C., Cole A.A., Sumner D.R., Valentino L.A. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008, 14:804-809.
13. Hooiveld M., Roosendaal G., Vianen M., van den Berg M., Bijlsma J., Lafeber F. Blood-induced joint damage: longterm effects invitro and invivo. JRheumatol 2003, 30:339-344.
14. Jansen N.W., Roosendaal G., Wenting M.J., Bijlsma J.W., Theobald M., Hazewinkel H.A., et al. Very rapid clearance after a joint bleed in the canine knee cannot prevent adverse effects on cartilage and synovial tissue. Osteoarthritis Cartilage 2009, 17:433-440.
15. Pettersson H., Ahlberg A., Nilsson I.M. Aradiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980, 153-159.
16. Doria A.S., Babyn P.S., Lundin B., Kilcoyne R.F., Miller S., Rivard G.E., et al. Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group. Haemophilia 2006, 12:503-513.
17. Jansen N.W., Roosendaal G., Lundin B., Heijnen L., Mauser-Bunschoten E., Bijlsma J.W., et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009, 60:290-298.
18. Fischer K., van Hout B.A., van der Bom J.G., Grobbee D.E., van den Berg H.M. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002, 43:528-532.
19. van Meegeren M.E., Roosendaal G., Jansen N.W., Wenting M.J., van Wesel A.C., van Roon J.A., et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage 2012, 20:764-772.
20. van Meegeren M.E., Roosendaal G., Coeleveld K., Nieuwenhuizen L., Mastbergen S.C., Lafeber F.P. Asingle intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice. Br J Haematol 2012, 160:515-520.
21. Narkbunnam N., Sun J., Hu G., Lin F.C., Bateman T.A., Mihara M., et al. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. JThromb Haemost 2013, 11:881-893.
22. van den Broek M., Visser K., Allaart C.F., Huizinga T.W. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 2013, 13:463-469.
23. Acharya S.S. Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management. Br J Haematol 2012, 156:13-23.
24. Di Minno M.N., Iervolino S., Peluso R., del Puente A., Russolillo A., Coppola A., et al. Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. Clin Rheumatol 2011, 30:915-919.
25. Pergantou H., Platokouki H., Matsinos G., Papakonstantinou O., Papadopoulos A., Xafaki P., et al. Assessment of the progression of haemophilic arthropathy in children. Haemophilia 2010, 16:124-129.
26. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
27. van Spil W.E., Drossaers-Bakker K.W., Lafeber F.P. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis 2013, 72:29-36.
28. van Spil W.E., Jansen N.W., Bijlsma J.W., Reijman M., Degroot J., Welsing P.M., et al. Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis. Osteoarthritis Cartilage 2012, 20:745-754.
29. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139.
30. Intema F., Sniekers Y.H., Weinans H., Vianen M.E., Yocum S.A., Zuurmond A.M., et al. Similarities and discrepancies in subchondral bone structure in two differently induced canine models of osteoarthritis. JBone Min Res 2010, 25:1650-1657.
31. Mundermann A., Dyrby C.O., Andriacchi T.P., King K.B. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis Cartilage 2005, 13:34-38.
32. Erhart-Hledik J.C., Favre J., Asay J.L., Smith R.L., Giori N.J., Mundermann A., et al. Arelationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years. Osteoarthritis Cartilage 2012, 20:1309-1315.
33. Neidhart M., Muller-Ladner U., Frey W., Bosserhoff A.K., Colombani P.C., Frey-Rindova P., et al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000, 8:222-229.
34. Glant T.T., Mikecz K., Roughley P.J., Buzas E., Poole A.R. Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J 1986, 236:71-75.
35. Matyas J.R., Atley L., Ionescu M., Eyre D.R., Poole A.R. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004, 50:543-552.
36. Mansson B., Carey D., Alini M., Ionescu M., Rosenberg L.C., Poole A.R., et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. JClin Invest 1995, 95:1071-1077.
37. Lohmander L.S., Ionescu M., Jugessur H., Poole A.R. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999, 42:534-544.